NVIV - InVivo Therapeutics Holdings Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

InVivo Therapeutics Holdings Corp.

One Kendall Square
Floor 4 Building 1400 East
Cambridge, MA 02139
United States
617-863-5500
http://www.invivotherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard M. ToselliPres, CEO, Chief Medical Officer & Director741.95kN/A1958
Dr. Robert S. Langer Jr.Co-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Joseph Philip VacantiCo-FounderN/AN/A1949
Mr. Richard C. ChristopherChief Financial OfficerN/AN/A1970
Mr. William D'Agostino PESr. VP of OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.